Accuray inks 10-year cancer tech agreement, shares in focus
Accuray Incorporated announced late Friday it’s entering a 10-year tie-up with the University of Wisconsin School of Medicine and Public Health. The two plan to work on customized cancer treatments with Accuray’s Stellar adaptive radiation therapy platform. Accuray put out the news after the Nasdaq close, a detail that mattered for the already struggling stock. Accuray’s deal comes at a time when the company is trying to show it can still draw clinical demand for its technology, even as investors turn their attention to its more troubled financial outlook. The Madison radiation-therapy systems maker pulled its fiscal 2026 guidance last week, blaming Middle East shipment delays, weaker service revenue, and ongoing uncertainty in China.
